The same test, regardless of cancer type
Researchers at the Institute for Cancer Genetics and Informatics at Oslo University Hospital (OUS), have developed a method that can assess the seriousness of a patient's cancer and what treatment is required. A test can help understand the development of almost all types of cancer, and the results are now published in The Lancet Oncology: Chromatin organization and cancer prognosis: a pan-cancer study.
Today, there is no common test to diagnose and predict cancer. Instead, a variety of tests and methods are used for different types of cancer. Very few of them can provide a certain answer as to how cancer will develop. The consequence is that it is difficult to distinguish patients who need more treatment after surgery from those who do not need ANY. A significant number of patients today receive too much treatment, which may cause unnecessary side effects, damage and at worst, death.
The fresh research results are based on more than 20 years of collaboration between the Department of Cancer Genetics and Informatics at OUS and the Department of Informatics at The University of Oslo.
Initially, the method will be particularly useful for finding patients with Stage II intestinal cancer who will need more treatment after surgery, usually chemotherapy. Experiments show that the method can also be used for ovarian cancer, uterine cancer and prostate cancer.
Click here to read more about the Nucleotyping method.
As a supplement to the article on the Lancet Oncology website, a 3d animation was made by our unit for Dissertation and Visualization:
Annual Report 2017 from ICGI
2017 marked the end of ten successful years of CCB and was also the first full year of the DoMore! Project, one of the prestigious Lighthouse projects awarded 60 million NOK by the Norwegian Research Council. With in silico pathology and an international consortium led by ICGI, the project aims to solve some of the large-scale societal challenges that cancer poses.
A summary of the Institute activities is reported in our annual report for 2017. Click here to download the pdf.
Animation on Deep Learning & Convolutional Networks
What can big data and deep learning do for cancer treatment? Watch our new video created by our researchers at www.domore.no and the Unit for Dissemination and Visualisation!
Click here to read our article on Deep Learning.
An article on Håkon Wæhres long time registration of patient data available in "Science Nordic"
After a life in service for prostate patients and fifty years of data collection, urologist Håkon Wæhre contributes to our research project DoMore! and the development of machines that will more accurately be able to assess how dangerous the patient's cancer is.
We truly appreciate Dr Wæhre's dedication to our research group at the ICGI. His presence and encouragements will be missed now he has chosen to retire.
Please click here to read the article in Science Nordic about how Dr. Wæhre's research efforts contribute to our DoMore! project.
Danielsen appointed Visiting Professor at University of Oxford
The University of Oxford's Medical Sciences Board has conferred on Håvard Danielsen the title of Visiting Professor of Cancer Informatics in recognition of his important contributions towards the successful and fruitful collaboration with their University.
The University of Oxford is a partner in the DoMore! project,, and Institute Director, Håvard E. Danielsen, also serves as chair of the panel of expertise in the Colorectal Cancer Research Collaboration Network ( crcnetwork.net),. The network includes representatives from some of the highest-ranked universities in Europe, the University of Oxford being among them.
Op-ed in "DN"
An op-ed authored by Elin Ersvær and Karolina Cyll, both PhD Candidates at the ICGI, and Institute Director Håvard E. Danielsen was published in "Dagens Næringsliv" (DN) 30th September. The Norwegian newspaper specializes in business news, and is the third largest newspaper in Norway. As part of their general coverage of health care businesses, big data and (cancer) research, DN has shown a keen interest in our Domore! project.
The institute's DoMore!-project makes computers understand how tumours evolve and what kind of treatment is needed, and the op-ed explains why present methods are insufficient. Click the image to read the article.
On Tuesday 19th September 2017, Andreas Kleppe defended his dissertation for the degree of Ph.D. at the Institute for Informatics at the University of Oslo. Colleagues and family were greatly impressed by the young Doctor who will continue his work at our Institute.
The trial lecture was entitled "Challenges and opportunities in digital pathology of tomorrow regarding multimodal data collection, machine learning and validation”. The topic of the dissertation was:
"Automatic detection of aberrant chromatin structure predicts prognosis in several cancer types".
Congratulations Dr. Kleppe!
Better knowledge base for treatment of endometrial cancer
Manohar Pradhan is a pathologist and one of our many great researchers. He has recently published a paper in Gynecologic Oncology, in collaboration with colleagues from the ICGI, the University of British Columbia and the University of Oxford. The findings reported will contribute to a better knowledge base for the choice of treatment for women with endometrial cancer.
Please find the article here: Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). Endometrial cancer is sometimes loosely referred to as "uterine cancer", although it is distinct from other forms of uterine cancer such as cervical cancer, uterine sarcoma, and trophoblastic disease. The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. Endometrial cancer is commonly diagnosed by endometrial biopsy or by taking samples during a procedure known as dilation and curettage. Though the five-year-survival rate after being diagnosed with endometrial cancer is >90%, this cancer type is the third most common cause of death in cancers which only affect women.
Doing More in Prognosis and Diagnosis
The ICGI is part of Oslo Cancer Cluster. Their story about ICGl, DoMore! and the significance of new technology development in the fight against cancer was published on their website during the summer of 2017.
Please click here to read the full article.
Prof. Håvard Danielsen appointed Scientist of the Month by The South-Eastern Norway Regional Health Authority for the month of June 2017
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of June 2017, this honour went to professor Håvard Danielsen, head of the Institute for Cancer Genetics and Informatics at Oslo University Hospital.
Read the article Lager en ny verden av analysemuligheter from the web pages of OUH (in Norwegian only).